Loading…

Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment

The term acute respiratory disease encompasses a wide range of acute lung diseases, which in recent years have been ranked among the top three deadly diseases in the world. Since conventional treatment methods, including the use of anti-inflammatory drugs, have had no significant effect on the treat...

Full description

Saved in:
Bibliographic Details
Published in:Pathology, research and practice research and practice, 2024-02, Vol.254, p.155135-155135, Article 155135
Main Authors: Jasim, Saade Abdalkareem, Aziz, Dhifaf Zeki, Mustafa, Yasser Fakri, Margiana, Ria, Al-Alwany, Ameen Abdulhasan, Hjazi, Ahmed, Alawadi, Ahmed, Yumashev, Alexey, Alsalamy, Ali, Fenjan, Mohammed N.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c305t-d6a8172f912863adbf496c18837da3e055f82cfce38de7bb4f5071aa95abb263
container_end_page 155135
container_issue
container_start_page 155135
container_title Pathology, research and practice
container_volume 254
creator Jasim, Saade Abdalkareem
Aziz, Dhifaf Zeki
Mustafa, Yasser Fakri
Margiana, Ria
Al-Alwany, Ameen Abdulhasan
Hjazi, Ahmed
Alawadi, Ahmed
Yumashev, Alexey
Alsalamy, Ali
Fenjan, Mohammed N.
description The term acute respiratory disease encompasses a wide range of acute lung diseases, which in recent years have been ranked among the top three deadly diseases in the world. Since conventional treatment methods, including the use of anti-inflammatory drugs, have had no significant effect on the treatment process of these diseases, the attention of the medical community has been drawn to alternative methods. Mesenchymal stem cells (MSC) are multipotential stem/progenitor cells that have extensive immunomodulatory and anti-inflammatory properties and also play a critical role in the microenvironment of injured tissue. MSC secretomes (containing large extracellular vesicles, microvesicles, and exosomes) are a newly introduced option for cell-free therapies that can circumvent the hurdles of cell-based therapies while maintaining the therapeutic role of MSC themselves. The therapeutic capabilities of MSCs have been showed in many acute respiratory diseases, including chronic respiratory disease (CRD), novel coronavirus 2019 (COVID −19), and pneumonia. MSCs offer novel therapeutic approaches for chronic and acute lung diseases due to their anti-inflammatory and immunomodulatory properties. In this review, we summarize the current evidence on the efficacy and safety of MSC-derived products in preclinical models of lung diseases and highlight the biologically active compounds present in the MSC secretome and their mechanisms involved in anti-inflammatory activity and tissue regeneration.
doi_str_mv 10.1016/j.prp.2024.155135
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2921114962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0344033824000463</els_id><sourcerecordid>2921114962</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-d6a8172f912863adbf496c18837da3e055f82cfce38de7bb4f5071aa95abb263</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi1ERZe2P4AL8pFLFo8dJ444VRVf0opKVe-WY0-Kl8QOthex_x6vtnDkNNLMM69mHkLeANsCg-79frumdcsZb7cgJQj5gmygA9WwTsBLsmGibRsmhLokr3PeM8Z61sIrcikUH2TbwYb8eIgz0jjRJwxYvDXzfKQYnnxATOjoghmD_X5czExzwYVanGeKv2OOdURNcHQX7MO320x9oAnz6pMpMR2p8xlNrkxJaMqCoVyTi8nMGW-e6xV5_PTx8e5Ls7v__PXudtdYwWRpXGcU9HwagKtOGDdO7dBZUEr0zghkUk6K28miUA77cWwnyXowZpBmHHknrsi7c-ya4s8D5qIXn09nm4DxkDUfOADUTF5ROKM2xZwTTnpNfjHpqIHpk2K9r51VnxTrs-K68_Y5_jAu6P5t_HVagQ9nAOuPvzwmna2vEtH5hLZoF_1_4v8ABtKOFA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2921114962</pqid></control><display><type>article</type><title>Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment</title><source>ScienceDirect Journals</source><creator>Jasim, Saade Abdalkareem ; Aziz, Dhifaf Zeki ; Mustafa, Yasser Fakri ; Margiana, Ria ; Al-Alwany, Ameen Abdulhasan ; Hjazi, Ahmed ; Alawadi, Ahmed ; Yumashev, Alexey ; Alsalamy, Ali ; Fenjan, Mohammed N.</creator><creatorcontrib>Jasim, Saade Abdalkareem ; Aziz, Dhifaf Zeki ; Mustafa, Yasser Fakri ; Margiana, Ria ; Al-Alwany, Ameen Abdulhasan ; Hjazi, Ahmed ; Alawadi, Ahmed ; Yumashev, Alexey ; Alsalamy, Ali ; Fenjan, Mohammed N.</creatorcontrib><description>The term acute respiratory disease encompasses a wide range of acute lung diseases, which in recent years have been ranked among the top three deadly diseases in the world. Since conventional treatment methods, including the use of anti-inflammatory drugs, have had no significant effect on the treatment process of these diseases, the attention of the medical community has been drawn to alternative methods. Mesenchymal stem cells (MSC) are multipotential stem/progenitor cells that have extensive immunomodulatory and anti-inflammatory properties and also play a critical role in the microenvironment of injured tissue. MSC secretomes (containing large extracellular vesicles, microvesicles, and exosomes) are a newly introduced option for cell-free therapies that can circumvent the hurdles of cell-based therapies while maintaining the therapeutic role of MSC themselves. The therapeutic capabilities of MSCs have been showed in many acute respiratory diseases, including chronic respiratory disease (CRD), novel coronavirus 2019 (COVID −19), and pneumonia. MSCs offer novel therapeutic approaches for chronic and acute lung diseases due to their anti-inflammatory and immunomodulatory properties. In this review, we summarize the current evidence on the efficacy and safety of MSC-derived products in preclinical models of lung diseases and highlight the biologically active compounds present in the MSC secretome and their mechanisms involved in anti-inflammatory activity and tissue regeneration.</description><identifier>ISSN: 0344-0338</identifier><identifier>EISSN: 1618-0631</identifier><identifier>DOI: 10.1016/j.prp.2024.155135</identifier><identifier>PMID: 38295461</identifier><language>eng</language><publisher>Germany: Elsevier GmbH</publisher><subject>Cell-free therapies ; Immunomodulation ; Inflammation ; Mesenchymal stem cell ; Respiratory disease ; Tissue regeneration</subject><ispartof>Pathology, research and practice, 2024-02, Vol.254, p.155135-155135, Article 155135</ispartof><rights>2024 Elsevier GmbH</rights><rights>Copyright © 2024 Elsevier GmbH. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c305t-d6a8172f912863adbf496c18837da3e055f82cfce38de7bb4f5071aa95abb263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38295461$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jasim, Saade Abdalkareem</creatorcontrib><creatorcontrib>Aziz, Dhifaf Zeki</creatorcontrib><creatorcontrib>Mustafa, Yasser Fakri</creatorcontrib><creatorcontrib>Margiana, Ria</creatorcontrib><creatorcontrib>Al-Alwany, Ameen Abdulhasan</creatorcontrib><creatorcontrib>Hjazi, Ahmed</creatorcontrib><creatorcontrib>Alawadi, Ahmed</creatorcontrib><creatorcontrib>Yumashev, Alexey</creatorcontrib><creatorcontrib>Alsalamy, Ali</creatorcontrib><creatorcontrib>Fenjan, Mohammed N.</creatorcontrib><title>Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment</title><title>Pathology, research and practice</title><addtitle>Pathol Res Pract</addtitle><description>The term acute respiratory disease encompasses a wide range of acute lung diseases, which in recent years have been ranked among the top three deadly diseases in the world. Since conventional treatment methods, including the use of anti-inflammatory drugs, have had no significant effect on the treatment process of these diseases, the attention of the medical community has been drawn to alternative methods. Mesenchymal stem cells (MSC) are multipotential stem/progenitor cells that have extensive immunomodulatory and anti-inflammatory properties and also play a critical role in the microenvironment of injured tissue. MSC secretomes (containing large extracellular vesicles, microvesicles, and exosomes) are a newly introduced option for cell-free therapies that can circumvent the hurdles of cell-based therapies while maintaining the therapeutic role of MSC themselves. The therapeutic capabilities of MSCs have been showed in many acute respiratory diseases, including chronic respiratory disease (CRD), novel coronavirus 2019 (COVID −19), and pneumonia. MSCs offer novel therapeutic approaches for chronic and acute lung diseases due to their anti-inflammatory and immunomodulatory properties. In this review, we summarize the current evidence on the efficacy and safety of MSC-derived products in preclinical models of lung diseases and highlight the biologically active compounds present in the MSC secretome and their mechanisms involved in anti-inflammatory activity and tissue regeneration.</description><subject>Cell-free therapies</subject><subject>Immunomodulation</subject><subject>Inflammation</subject><subject>Mesenchymal stem cell</subject><subject>Respiratory disease</subject><subject>Tissue regeneration</subject><issn>0344-0338</issn><issn>1618-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kE1v1DAQhi1ERZe2P4AL8pFLFo8dJ444VRVf0opKVe-WY0-Kl8QOthex_x6vtnDkNNLMM69mHkLeANsCg-79frumdcsZb7cgJQj5gmygA9WwTsBLsmGibRsmhLokr3PeM8Z61sIrcikUH2TbwYb8eIgz0jjRJwxYvDXzfKQYnnxATOjoghmD_X5czExzwYVanGeKv2OOdURNcHQX7MO320x9oAnz6pMpMR2p8xlNrkxJaMqCoVyTi8nMGW-e6xV5_PTx8e5Ls7v__PXudtdYwWRpXGcU9HwagKtOGDdO7dBZUEr0zghkUk6K28miUA77cWwnyXowZpBmHHknrsi7c-ya4s8D5qIXn09nm4DxkDUfOADUTF5ROKM2xZwTTnpNfjHpqIHpk2K9r51VnxTrs-K68_Y5_jAu6P5t_HVagQ9nAOuPvzwmna2vEtH5hLZoF_1_4v8ABtKOFA</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>Jasim, Saade Abdalkareem</creator><creator>Aziz, Dhifaf Zeki</creator><creator>Mustafa, Yasser Fakri</creator><creator>Margiana, Ria</creator><creator>Al-Alwany, Ameen Abdulhasan</creator><creator>Hjazi, Ahmed</creator><creator>Alawadi, Ahmed</creator><creator>Yumashev, Alexey</creator><creator>Alsalamy, Ali</creator><creator>Fenjan, Mohammed N.</creator><general>Elsevier GmbH</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202402</creationdate><title>Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment</title><author>Jasim, Saade Abdalkareem ; Aziz, Dhifaf Zeki ; Mustafa, Yasser Fakri ; Margiana, Ria ; Al-Alwany, Ameen Abdulhasan ; Hjazi, Ahmed ; Alawadi, Ahmed ; Yumashev, Alexey ; Alsalamy, Ali ; Fenjan, Mohammed N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-d6a8172f912863adbf496c18837da3e055f82cfce38de7bb4f5071aa95abb263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cell-free therapies</topic><topic>Immunomodulation</topic><topic>Inflammation</topic><topic>Mesenchymal stem cell</topic><topic>Respiratory disease</topic><topic>Tissue regeneration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jasim, Saade Abdalkareem</creatorcontrib><creatorcontrib>Aziz, Dhifaf Zeki</creatorcontrib><creatorcontrib>Mustafa, Yasser Fakri</creatorcontrib><creatorcontrib>Margiana, Ria</creatorcontrib><creatorcontrib>Al-Alwany, Ameen Abdulhasan</creatorcontrib><creatorcontrib>Hjazi, Ahmed</creatorcontrib><creatorcontrib>Alawadi, Ahmed</creatorcontrib><creatorcontrib>Yumashev, Alexey</creatorcontrib><creatorcontrib>Alsalamy, Ali</creatorcontrib><creatorcontrib>Fenjan, Mohammed N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology, research and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jasim, Saade Abdalkareem</au><au>Aziz, Dhifaf Zeki</au><au>Mustafa, Yasser Fakri</au><au>Margiana, Ria</au><au>Al-Alwany, Ameen Abdulhasan</au><au>Hjazi, Ahmed</au><au>Alawadi, Ahmed</au><au>Yumashev, Alexey</au><au>Alsalamy, Ali</au><au>Fenjan, Mohammed N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment</atitle><jtitle>Pathology, research and practice</jtitle><addtitle>Pathol Res Pract</addtitle><date>2024-02</date><risdate>2024</risdate><volume>254</volume><spage>155135</spage><epage>155135</epage><pages>155135-155135</pages><artnum>155135</artnum><issn>0344-0338</issn><eissn>1618-0631</eissn><abstract>The term acute respiratory disease encompasses a wide range of acute lung diseases, which in recent years have been ranked among the top three deadly diseases in the world. Since conventional treatment methods, including the use of anti-inflammatory drugs, have had no significant effect on the treatment process of these diseases, the attention of the medical community has been drawn to alternative methods. Mesenchymal stem cells (MSC) are multipotential stem/progenitor cells that have extensive immunomodulatory and anti-inflammatory properties and also play a critical role in the microenvironment of injured tissue. MSC secretomes (containing large extracellular vesicles, microvesicles, and exosomes) are a newly introduced option for cell-free therapies that can circumvent the hurdles of cell-based therapies while maintaining the therapeutic role of MSC themselves. The therapeutic capabilities of MSCs have been showed in many acute respiratory diseases, including chronic respiratory disease (CRD), novel coronavirus 2019 (COVID −19), and pneumonia. MSCs offer novel therapeutic approaches for chronic and acute lung diseases due to their anti-inflammatory and immunomodulatory properties. In this review, we summarize the current evidence on the efficacy and safety of MSC-derived products in preclinical models of lung diseases and highlight the biologically active compounds present in the MSC secretome and their mechanisms involved in anti-inflammatory activity and tissue regeneration.</abstract><cop>Germany</cop><pub>Elsevier GmbH</pub><pmid>38295461</pmid><doi>10.1016/j.prp.2024.155135</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0344-0338
ispartof Pathology, research and practice, 2024-02, Vol.254, p.155135-155135, Article 155135
issn 0344-0338
1618-0631
language eng
recordid cdi_proquest_miscellaneous_2921114962
source ScienceDirect Journals
subjects Cell-free therapies
Immunomodulation
Inflammation
Mesenchymal stem cell
Respiratory disease
Tissue regeneration
title Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T19%3A18%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20genetically%20engineered%20mesenchymal%20stem%20cell%20exosomes%20and%20LncRNAs%20in%20respiratory%20diseases%20treatment&rft.jtitle=Pathology,%20research%20and%20practice&rft.au=Jasim,%20Saade%20Abdalkareem&rft.date=2024-02&rft.volume=254&rft.spage=155135&rft.epage=155135&rft.pages=155135-155135&rft.artnum=155135&rft.issn=0344-0338&rft.eissn=1618-0631&rft_id=info:doi/10.1016/j.prp.2024.155135&rft_dat=%3Cproquest_cross%3E2921114962%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c305t-d6a8172f912863adbf496c18837da3e055f82cfce38de7bb4f5071aa95abb263%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2921114962&rft_id=info:pmid/38295461&rfr_iscdi=true